Adlai Nortye logo

Adlai Nortye

ANL | NASDAQ
Chart Builder DCF Calculator
$10.03
-$0.58 (-5.47%)
At close: Nov 16, 2026, 4:00 PM ET
$10.03
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET
-5.47%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
53.2
Fundamentals Strong
Market Sentiment Neutral
Moat None
Sector Rank #215/1021 (Top 21%)

Key Statistics

Market Data

Market Cap $532.39M
1D Range
9.80 11.00
52W Range
0.88 16.60

Valuation (TTM)

PE -5.14
PB 2.48
EV/EBITDA -15.57

Valuation (NTM)

Forward PE 5.06
Forward PEG 0.14
Price Target $32.00
Loading financial charts...

Profile

Adlai Nortye Ltd. (ANL) is a clinical-stage biotechnology firm dedicated to the research and development of innovative pharmaceutical products. Their flagship compound, AN2025, a pan-phosphoinositide ...

Sector Healthcare
Industry Biotechnology
Employees 109
IPO Date Sep 29, 2023
Fiscal Year January - December

Latest News

No news articles available yet.

Earnings

Next Earnings
Mar 3, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
1
Consensus
Buy
Price Target
$32.00
Upside
+219.04%
Buy (1)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.